Pathstone Holdings LLC Sells 10,548 Shares of Cencora, Inc. (NYSE:COR)

Pathstone Holdings LLC lowered its stake in Cencora, Inc. (NYSE:COR) by 19.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 44,720 shares of the company’s stock after selling 10,548 shares during the period. Pathstone Holdings LLC’s holdings in Cencora were worth $10,048,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. JFS Wealth Advisors LLC increased its position in shares of Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock worth $27,000 after purchasing an additional 46 shares during the period. Banque Transatlantique SA bought a new position in Cencora in the fourth quarter valued at about $29,000. SBI Securities Co. Ltd. bought a new position in Cencora in the fourth quarter valued at about $30,000. Householder Group Estate & Retirement Specialist LLC grew its position in Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after acquiring an additional 69 shares during the last quarter. Finally, Kentucky Trust Co bought a new position in Cencora in the fourth quarter valued at about $33,000. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling

In related news, EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the transaction, the executive vice president now directly owns 15,374 shares of the company’s stock, valued at $3,724,197.76. The trade was a 24.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Steven H. Collis sold 14,579 shares of Cencora stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total value of $4,108,507.99. Following the completion of the transaction, the chairman now directly owns 315,913 shares in the company, valued at approximately $89,027,442.53. This represents a 4.41% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 50,223 shares of company stock valued at $13,580,967 over the last ninety days. 10.80% of the stock is owned by company insiders.

Cencora Price Performance

Cencora stock opened at $285.51 on Friday. The stock’s 50 day moving average is $278.51 and its 200 day moving average is $254.58. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The firm has a market cap of $55.37 billion, a P/E ratio of 40.61, a P/E/G ratio of 1.31 and a beta of 0.60. Cencora, Inc. has a one year low of $214.77 and a one year high of $309.35.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, topping analysts’ consensus estimates of $4.07 by $0.35. The company had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm earned $3.80 earnings per share. As a group, research analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 2nd. Investors of record on Friday, May 16th will be paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.77%. The ex-dividend date is Friday, May 16th. Cencora’s dividend payout ratio is currently 25.52%.

Wall Street Analyst Weigh In

A number of research firms have issued reports on COR. Robert W. Baird lifted their target price on Cencora from $314.00 to $350.00 and gave the company an “outperform” rating in a research report on Thursday, May 8th. Evercore ISI lifted their target price on Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. Citigroup lifted their target price on Cencora from $330.00 to $355.00 and gave the company a “buy” rating in a research report on Thursday, May 8th. StockNews.com upgraded Cencora from a “hold” rating to a “buy” rating in a report on Wednesday, March 12th. Finally, UBS Group boosted their price target on Cencora from $298.00 to $335.00 and gave the stock a “buy” rating in a report on Tuesday, April 29th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, Cencora has a consensus rating of “Moderate Buy” and a consensus price target of $301.18.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.